Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021
Net Sales 203.86 221.2 213.68 217.84 242.05
Total Expenditure 160.89 172.97 165.57 176.66 190.99
Operating Profit 42.97 48.23 48.12 41.18 51.06
Other Income 5.93 5.79 8.84 2.56 5.95
Interest 25.04 24.96 25.91 24.31 24.12
Depreciation 19.69 19.85 19.83 27.93 14.06
Exceptional Items 0 0 0 0 0
Profit Before Tax 4.17 9.22 11.22 -8.5 18.83
Tax 0 0 0 20.52 0.08
Profit After Tax 4.17 9.22 11.22 -29.02 18.75
Adjusted EPS (Rs) 0.71 1.56 1.9 -4.91 3.17

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
Profit from operations -68.55 -50.85 30.52 -24.01 -19.56
Adjustment 186.52 167.95 103.64 176.17 176.02
Changes in Assets & Liabilities -37.53 -24.43 -62.7 -226.79 -33.3
Tax Paid 0 0 0 0 0
Operating Cash Flow 80.44 92.67 71.46 -74.63 123.16
Investing Cash Flow -29.56 -30.99 -17.25 -2.34 -10.15
Financing Cash Flow -47.92 -68.9 -61.98 99.62 -133.26
Net Cash Flow 2.95 -7.22 -7.78 22.66 -20.25

Investors Details

PARTICULARS Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021
Public 38.5 38.47 38.47 38.34 38.46
sri ganesh biotech privat... 1.18 1.18 1.18 1.21 1.26
iepf 0.27 0.26 0.26 0.26 0.26
gryffin advisory services... 1.72 0 0 0 0
edelweiss asset reconstru... 0 0 0 0 0
ashokkumar chandak 3.62 3.45 3.58 3.19 2.79
conquer investment & fina... 1.12 1.12 1.12 1.18 1.18
bsas infotech ltd 0 1.72 1.43 0 0
PARTICULARS Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021
FII/DII 19.49 19.54 19.54 19.66 19.55
ec special situations fun... 6.82 6.82 6.82 6.82 6.82
edelweiss india special s... 10.43 10.43 10.43 10.43 10.43
eisaf ii onshore fund 2.24 2.24 2.24 2.24 2.24

Company Presentations

Ind-Swift Lab. Stock Price Analysis and Quick Research Report. Is Ind-Swift Lab. an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Ind-Swift Lab. and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 123.1641 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Ind-Swift Lab. has a Debt to Equity ratio of 2.3809 , which is a weak indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Ind-Swift Lab. , the EPS growth was -143.37870829326 % which is bad for the company.
     
  • Operating profit margin: It determines a companys potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Ind-Swift Lab. has OPM of 18.7622616273146 % which is a good sign for profitability.
     
  • ROE: Ind-Swift Lab. have a poor ROE of -5.40919612522185 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholders fund is used for generating profits.
Brief about Ind-Swift Lab.

Reach out

Find us at the office

Exel- Frazzitta street no. 61, 44925 Kingston, Norfolk Island

Give us a ring

Jovanny Boeding
+23 274 947 142
Mon - Fri, 10:00-21:00

Tell us about you